ALLO
Allogene Therapeutics, Inc.Company with tickers: ALLO
Market Cap
$711.02M
Shares Outstanding
345,154,561
CIK
1737287
CUSIP
019770106
13F Activity (30d)
2 filings
1 filers
Website
Visit website
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $0 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Cost of Revenue | $200,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Gross Profit | — | ||||
| Operating Expenses | $46,092,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Research & Development | $32,003,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-46,092,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-42,607,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-0.18 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-0.18 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Reportable Segment | $95,000 | $22,000 | $0 |